Hainan Huluwa Pharmaceutical Group Co., Ltd. (605199.SS)
CNY 19.25
(-3.12%)
CNY 19.25
(-3.12%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 739.49 Million CNY | 314.51% |
| 2022 | 178.4 Million CNY | 4249.97% |
| 2021 | 4.1 Million CNY | -92.12% |
| 2020 | 52.04 Million CNY | 215.43% |
| 2019 | 16.5 Million CNY | -45.94% |
| 2018 | 30.52 Million CNY | -56.22% |
| 2017 | 69.72 Million CNY | -33.52% |
| 2016 | 104.87 Million CNY | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q3 | 597.39 Million CNY | -0.77% |
| 2024 Q2 | 602.02 Million CNY | 10.73% |
| 2024 Q1 | 545.49 Million CNY | -26.27% |
| 2023 Q3 | 759.56 Million CNY | 42.06% |
| 2023 Q2 | 534.69 Million CNY | 45.56% |
| 2023 FY | 739.49 Million CNY | 314.51% |
| 2023 Q1 | 367.32 Million CNY | 105.9% |
| 2023 Q4 | 739.49 Million CNY | -2.64% |
| 2022 Q4 | 178.4 Million CNY | 9178.84% |
| 2022 Q3 | 1.92 Million CNY | -32.64% |
| 2022 Q2 | 2.85 Million CNY | -18.8% |
| 2022 Q1 | 3.51 Million CNY | -14.29% |
| 2022 FY | 178.4 Million CNY | 4249.97% |
| 2021 Q1 | 110.65 Million CNY | 112.6% |
| 2021 Q4 | 4.1 Million CNY | -94.83% |
| 2021 FY | 4.1 Million CNY | -92.12% |
| 2021 Q2 | 121.83 Million CNY | 10.1% |
| 2021 Q3 | 79.3 Million CNY | -34.91% |
| 2020 Q2 | 16.5 Million CNY | 0.0% |
| 2020 Q4 | 52.04 Million CNY | 333.72% |
| 2020 FY | 52.04 Million CNY | 215.43% |
| 2020 Q3 | 12 Million CNY | -27.27% |
| 2020 Q1 | 16.5 Million CNY | 0.0% |
| 2019 Q2 | 22.57 Million CNY | 0.0% |
| 2019 FY | 16.5 Million CNY | -45.94% |
| 2019 Q1 | - CNY | 0.0% |
| 2019 Q4 | 16.5 Million CNY | 0.0% |
| 2018 FY | 30.52 Million CNY | -56.22% |
| 2017 FY | 69.72 Million CNY | -33.52% |
| 2016 FY | 104.87 Million CNY | 0.0% |